Development of Stimuli-Responsive Nanoparticle-carrying T lymphocytes in the Fight against Cancer

Projektinformationen

CellularNanoMachines

ID Finanzhilfevereinbarung: 796672

DOI 10.3030/796672

Abgeschlossenes Projekt

EK-Unterschriftsdatum 7 März 2018

Startdatum 4 Januar 2019

Enddatum 3 Januar 2022

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 240 530,40

EU-Beitrag € 240 530,40

Koordiniert durch

KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium

Ziel

The cancer burden represents an overarching health problem and it is essential that EU institutions develop the next generation of diagnostics that overcome the inadequacy of current imaging strategies. Nanomedicine, defined as the use of nanotechnologies in medicine, offers extraordinary opportunities to address these unmet medical needs. The proposed research project endeavours to find effective anticancer diagnostics through the development of smart cellular nano-machines. The design will integrate white blood cells (concretely, tumour-targeted T lymphocytes) as living carriers of stimuli-responsive drug-loaded NPs. The tumour-homing T cells will facilitate NP accumulation in tumours until an internal/external stimulus triggers NP-release. The NPs will also possess imaging capabilities to visualize and monitor the injected formulations and confirm that the designed NPs target cancer cells in vivo. This approach aims to achieve highly versatile, selective and effective nanomedicine products that combine imaging and therapy for different types of cancer (theranostics). The strategy will provide anticancer materials compatible with industrial processes and personalized medicine. Thus, I believe the results arising from this work will place EU institutions in an unbeatable position to capitalize on the next generation of diagnostics, not only to boost the competitiveness of our industries but also to make positive changes in the lives of our citizens.

Wissenschaftliches Gebiet

• engineering and technology › nanotechnology
• medical and health sciences › medical biotechnology › nanomedicine
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › health sciences › personalized medicine

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2017 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2017

Finanzierungsplan

MSCA-IF-GF - Global Fellowships

Koordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

• Netto-EU-Beitrag: € 240 530,40
• Adresse: OUDE MARKT 13 ; 3000 Leuven ; Belgien
• Region: Vlaams Gewest › Prov. Vlaams-Brabant › Arr. Leuven
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 240 530,40

Partner (1)

Partner

Partnerorganisationen tragen zur Umsetzung der Aktion bei, unterzeichnen jedoch nicht die Finanzhilfevereinbarung.

Sloan-Kettering Institute for Cancer Research CORPORATION

Vereinigte Staaten

• Netto-EU-Beitrag: € 0,00
• Adresse: York Avenue 1275 ; 10065 New York
• Aktivitätstyp: Research Organisations
• Gesamtkosten: € 160 130,40